Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.
Publication/Presentation Date
7-1-2021
Abstract
We evaluate the safety of bendamustine as a bridge to stem cell transplantation (SCT) in patients with relapsed/refractory lymphoma and residual disease after salvage therapy. Thirty-four subjects without complete responses (CR) received bendamustine 200 mg/m
Volume
62
Issue
7
First Page
1629
Last Page
1638
ISSN
1029-2403
Published In/Presented At
Orfali, N., Jhanwar, Y., Koo, C., Pasciolla, M., Baldo, M., Cuvilly, E., Furman, R., Gergis, U., Greenberg, J., Guarneri, D., Hsu, J. M., Leonard, J. P., Mark, T., Mayer, S., Maignan, K., Martin, P., Opong, A., Pearse, R., Phillips, A., Rossi, A., … Shore, T. (2021). Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & lymphoma, 62(7), 1629–1638. https://doi.org/10.1080/10428194.2021.1881516
Disciplines
Medicine and Health Sciences
PubMedID
33586581
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article